Since October 2024, Cigna has been in a holding pattern, posting a small loss of 1% while floating around $338.25. However, the stock is beating the S&P 500’s 6.9% decline during that period.
The FTC has paused its antitrust case against major PBMs, citing a lack of commissioners. The lawsuit alleges unfair practices that inflated insulin prices.
Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the health insurance providers industry, including Molina Healthcare (NYSE:MOH) and its peers.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Progyny (NASDAQ:PGNY) and its peers.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Forest Hills, NY - Empire Psychiatry comprises top-rated professionals passionate about helping individuals with mental illness or those seeking guidance and counseling. The mental health facility serves children, adolescents, and adults using individualized, comprehensive care in a safe and confidential environment.
Shares of major healthcare companies such as The Cigna Group Inc. (NYSE: CI), Molina Healthcare Inc. (NYSE: MOH) and UnitedHealth Group Inc. (NYSE: UNH) dropped Wednesday following the signing of an executive order by President Donald Trump aimed at strengthening price transparency regulations in the industry.
The Justice Department is investigating UnitedHealth's Medicare billing practices, focusing on diagnoses that led to higher federal payments. The probe follows reports that the company received billions for questionable diagnoses in its Medicare Advantage plans.
Humana is the second largest health insurance provider of Medicare Advantage (MA) plans sounding the alarms of rising medical costs but will now cut 10%
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has weighed on the returns lately as the industry has pulled back by 1.7% over the past six months. This performance is a noticeable divergence from the S&P 500’s 9% return.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This drop is a stark contrast from the S&P 500’s 9% gain.
